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Abstract
Background: The Multiplex Ligation-dependent Probe Amplification (MLPA) is widely used for analysis of copy 
number variations (CNVs) in single or multiple loci. MLPA is a versatile methodology and important tool in cancer 
research; it provides precise information on increased or decreased copy number at specific loci as opposed to loss of 
heterozygosity (LOH) studies based upon microsatellite analysis. Pre-designed MLPA kits and software are 
commercially available to analyze multiple exons, genes, and genomic regions. However, an increasing demand for 
new gene specific assays makes it necessary to self-design new MLPA probes for which the available software may not 
be applicable. During evaluation of new self-designed reference probes, we encountered a number of problems, 
especially when applying the MLPA methodology to tumor samples.
Findings: DNA samples from 48 unaffected individuals and 145 breast cancer patients were used to evaluate 11 self-
designed MLPA probes and determine the cut-off values for CNV, before applying the MLPA probes to normalize the 
target probes in a cohort of affected individuals. To test the calculation strategy, three probes were designed to cover 
regions in Regulator of G-protein Signaling 8 (RGS8), which we previously have identified as being affected by allelic 
imbalance by LOH analysis across RGS8 in the cohort comprising 145 breast tumors. Agreement between the LOH 
results and the results obtained by each of the three MLPA probes in RGS8 was found for 64%, 73%, and 91%, of the 
analyzed samples, respectively.
Conclusion: Here, we present a straightforward method, based upon the normalization pattern in both unaffected 
and affected individuals, to evaluate self-designed reference probes and to calculate CNV for the MLPA assay with 
specific focus on the difficulties when analyzing tumor DNA.
Background
Copy number variations (CNV), including deletions or
duplications of whole chromosomes and minor frag-
ments down to single exons are implicated in the onset
and risk of human congenital and somatic diseases [1].
The Multiplex Ligation-dependent Probe Amplification
(MLPA) is widely used both in research and clinical labo-
ratories and is a promising methodology to assess CNV
[2]. MLPA assays provide highly detailed information on
CNV, from chromosome aneuploidy down to single
exons. The methodology is fast and straightforward to
perform, standard laboratory equipment is used, and a
limited amount of DNA (20 ng/analysis) is necessary to
provide high quality and reproducible results. Ligation-
dependent PCR amplification was first described by
Hsuih et al. [3] further developed by Schouten et al. [4]
and a growing number of predesigned gene specific
MLPA assays is commercially available from MRC Hol-
land http://www.mrc-holland.com. The MLPA method-
ology is versatile and can be applied to different analyses
as assessment of genomic copy number variations
(CNV), DNA methylation status of specific loci (MS-
MLPA), evaluation of chromosomal break points, CGH
results, and gene expression profiles (RT-MLPA) [5-8].
The advantage is that multiple loci can be analyzed
simultaneously and software is available to perform the
tedious calculations.
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Current research involving MLPA is mainly based on
the commercially available MLPA kits targeting specific
genes (MRC-Holland, Amsterdam, The Netherlands),
which significantly shorten the optimization time and
facilitates data analysis, as specific software is available to
analyze the results.
However, the increasing demand for new gene specific
assays makes it necessary to self-design individual probes
for the analysis [9]. Establishment of CNV is based upon
results obtained from reference probes, which are
included in each individual assay and used to normalize
the values obtained from the target genes. Specific care
has to be taken when analyzing tumor genomes, as some
of these reference genes may be located in regions
affected by cancer specific CNV [10-12].
Here, we describe the evaluation of self-designed refer-
ence probes, using a cohort of unaffected and affected
individuals, to determine the quality and the cut-off val-
ues determining CNV, before applying and using the ref-
erence probes to normalize self-designed target probes in
tumor samples. To evaluate our calculation strategy we
aimed to determine CNV in Regulator of G-protein Sig-
naling 8 (RGS8), which previously has been identified as
allelic imbalance by a combination of loss of heterozygos-
ity (LOH) analysis and PCR mapping (unpublished
results).
Samples
Breast tumor DNA was isolated from 145 women diag-
nosed with unilateral primary breast cancer. The cohort
was collected between August 1992 and January 1994 and
described in [13]. DNA isolated from peripheral blood
was obtained from healthy Danish medical students in
their first year of University. All DNA was isolated
according to [14].
The respective local ethical committees have approved
the use of these samples.
Probe design and MLPA assay
Probes for the MLPA assays were designed according to
"Improved synthetic probe design protocol" available on
http://www.mrc-holland.com, and the guidelines were
followed carefully.
Eleven probes were synthesized at 40 nmol synthesis
scale and purchased from TAG Copenhagen A/S (Copen-
hagen, Denmark). FAM-labeled universal MLPA primers
were used to enable simultaneous probe amplification.
Probe mixes, used for further analysis, consisted of 0.8-
1.6 μl of each 1 μM probe solution in a total volume of
400 μl. Primer sequences are listed in Table 1.
The MLPA protocol (MLPA®DNA protocol) was per-
formed using the instructions provided by the company
http://www.mrc-holland.com and initially described by
Schouten et al. [4].
The MLPA assay was performed using sets of self-
designed probes and the EK5 SALSA MLPA reagents kit
purchased from MRC-Holland (Amsterdam, The Nether-
lands). Briefly, 10 ng of genomic DNA in a volume of 5 μl
was denatured for 5 min at 98°C, cooled and hybridized
with MLPA probes (1.5 μl/sample) in the presence of
SALSA MLPA buffer (1.5 μl/sample) for 16 h at 60°C.
Ligation reaction was performed for 15 min at 54°C by
adding 32 μl of ligation mixture (3 μl SALSA Ligase buf-
fers A and B, respectively, 25 μl demineralized water, and
1 μl SALSA Ligase-65/sample) followed by heating to
95°C for 5 min. PCR amplification of the ligation product
was performed according to the standard protocol.
Briefly, 5 μl of the ligation product was added to the mix-
ture consisting of (15.75 μl demineralized water, 2 μl
SALSA-PCR buffer, 1 μl SALSA-enzyme dilution buffer, 1
μl SALSA FAM PCR primers and 0.25 μl SALSA poly-
merase/sample) while the samples were left at 4°C or on
ice. The samples were pre-heated to 60°C for 20 s, fol-
lowed by 35 cycles of 95°C for 30 s, 60°C for 40 s, 72°C for
1 min, and a final extension for 20 min at 72°C. From each
PCR reaction, 1.0 μl product was mixed with 9 μl of
deionized formamide (Amresco, Solon, Ohio) and 0.3 μl
of Genescan-Rox 500 size standard (Applied Biosystems,
Foster City, CA, USA) and all fragments were separated
by capillary electrophoresis on the ABI 3130XL Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
Evaluation of reference probes
Ten DNA samples obtained from unaffected individuals
were analyzed in a pilot study to evaluate the general peak
pattern of the reference probes in a multiplex set-up.
To secure that the self-designed reference probes were
normally distributed, they were evaluated using DNA
samples from 48 unaffected and 145 affected individuals.
Following the MLPA analysis, all fragment-specific peaks,
obtained from capillary electrophoresis, corresponding
to specific probes were identified by GeneMapper™
(Applied Biosystems, Foster City, CA, USA) applying the
Amplified Fragment Length Polymorphism (AFLP) anal-
ysis method. It should be taken into consideration that
the AFLP algorithm automatically normalizes the peak
heights and that this option should be turned off (recom-
mended by Applied Biosystems). Data of peak height and
fr a gm e n t  l e n gt h  w e r e  i m po rt ed  i n t o  a  M i cr os o ft  E x c e l
spreadsheet for further analysis.
Peak heights of the reference probes were analyzed in a
Gaussian Q-Q plot and in a histogram, where all refer-
ence probe peaks have to show the same normalization
pattern in both affected and unaffected individuals; oth-
erwise, the probe is omitted from further studies 1. If the
samples were overloaded, dilution of the MLPA product
should be avoided as it may affect the final result. Instead,
we suggest changing the injection time or voltage accord-Pedersen et al. BMC Research Notes 2010, 3:179
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ing to recommendations from MRC Holland. If the prob-
lem persists, the volume of probes in the probe mix can
be decreased as well as the MLPA product before the cap-
illary electrophoresis. The important issue is to treat all
samples from unaffected and affected individuals in
exactly the same way throughout the MLPA analysis.
Normalization of MLPA probes and CNV calculations
CNV was established in the tumor samples by normaliza-
tion of the target probe to all reference probes present in
the run. Next, standard deviation and mean value of the
probe of interest were calculated from the cohort of unaf-
fected individuals to establish the z score in the tumor
samples. Normalized peak height ratios for each target
probe in both tumor samples and unaffected individuals
were calculated as:
, where a  is the peak
height of the target probe and C1-n is the peak height of
each reference probe 1 - n. In this case the normalization
of the probe height takes into account the specific peak
profile and the ratio of the reference probe in the sample.
When assessing the quantitative value of each probe,
both the peak height and the peak area can be used. We
experienced that the peak height provided the most con-
sistent results (data not shown).
Since the normalized peak heights were normally dis-
tributed, the z score of normalized peak heights (x) in
tumor samples was found as  , where μ and σ
are the estimated mean and standard deviation of the
normalized peak heights for the population of unaffected
individuals. To determine CNV for each probe, the distri-
bution of normalized peak heights can be determined
from the group of unaffected individuals and the cut-off
values determined as fractils from the normal distribu-
tion. When the z score was calculated, the cut-off values
could be determined from the standard normal distribu-
tion, in which +/- 1.96 is equivalent to a 5% cut-off value.
Moreover, all probes in a region analyzed together can
be evaluated in combination to provide an overall mea-
sure of gain or loss. If there are k probes in the region, and
an individual has the probe z scores z1,...,zk, the combined
z score is  . Under the null hypothesis that
z 1,...,zk are standard normal distributed, the z' is standard
normally distributed too and can be evaluated in the
same way as the z scores for each probe.
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Table 1: The set of synthetic oligonucleotide probes used in the MLPA assay.
Probe name Location Length (bp) Left probe hybridizing sequence Right probe hybridizing sequence
ARX Xp21.3 83 CGAATGCCGGGCTGATGAAAG CTGGGTGTCGGAACACTGCC
AFAP1L1a 5q33.1 90 CCTACACTAACACATGATGAAAACC TCAATATGTCCTCAGGTGGTACC
ACTR1A 10q24.32 102 GGATGAGTTAATTCACACAGCTTTG TCAGAGCCCTCATGCAGCCTCTTGTAAGCAGAT
AG
AFAP1L1b 5q33.1 114 GAGACAAGACCTGATCATCTGATCACACTT GTGCCAACTTGATTCATATTGGGCATTACTAACA
ACCCCTGG
CFL2 14q13.2 132 ctgacCGTGCTGCCATATCACTAAAATAGGCTTGCC
AAGG
CAGGTGAGGTGTATGAATGCTCAAGCCTCACAG
AACTGCAATCAAGTGCC
P1 1q25.3 106 gctaCTCCAGAGCAAATAAGCATGG ACCTCAAGAATGAATTGATGTACCAGTTGGAga
ctgact
P2 1q25.3 122 CAAGAAGACCAGGTCAACTGCAAAACTGGT CTCTAAGGCCCATAGGATCTTTGAGGAGTTTGT
GGATGTGCAGGCTCCAC
P3 1q25.3 127 gactgactgactCCGTAAATGAACGTATGCTGAACATG ATCCGTCAGATCTCTAGACCCTCAGCTgactgact
gactgactgact
Fr. 14 1q25.3 101 GAGGACGTGAACCAGGACCGTAAGGA CATGAGCCAGAGCAGTGGTAGCGAGGATGGAG
G
Fr. 31 1q25.3 107 TGGGCAGATTCCTTTGATGTGCTTC TCTCTCATAAGTGTAAGTAGAATTCAGGTCGTAT
CATGAC
Fr. 32 1q25.3 119 gactGACCTGCGTTCTTGATTTTGACTCAGCG TTGTTACTAAGTAGTTGGGTGGTCTTGACAGAA
ACTCgactgact
Upper case correspond to the left and right hybridizing sequence of each probe, whereas lower case correspond to the stuffer sequences used 
to increase the size of the probe; underlined probes concern the reference probes analyzed in this study.Pedersen et al. BMC Research Notes 2010, 3:179
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The Microsoft Office Excell (version 2007) and JMP®
Software were used for analyses.
Analyses of reference probes for MLPA assay
DNA samples from 48 unaffected individuals and 145
breast tumors were successfully analyzed using 11 self-
designed MLPA probes. The peak heights of all five refer-
ence probes (ARX, AFAP1L1a, AFAP1L1b, ACTR1A,
CFL2) were normalized to each other, the z score was cal-
culated and further evaluated in a Q-Q plot to verify the
distribution. Based on these analyses, the ARX,
AFAP1L1a and ACTR1A reference probes did not meet
the requirements as they varied significantly in samples
from both cohorts. AFAP1L1b and CFL2 showed no sig-
nificant variation between unaffected and affected indi-
viduals and were included in the following CNV analyses.
An example of the evaluation in a Gaussian Q-Q plot
conducted on the analyzed reference probes is shown in
figure 1.
Validation of CNV by RGS8 specific MLPA assay
Three MLPA self-designed target probes were included
in a MLPA study to validate the CNV calculation method.
All probes were located within specific regions of RGS8,
which previously has been identified as being affected by
allelic imbalance by detailed LOH analysis in breast can-
cer samples (manuscript in preparation). Exact location
of the affected regions was performed by PCR amplifica-
tion of overlapping fragments throughout the affected
region. None of these methods provide unambiguous
CNV results. Previously analyzed reference probes
AFAP1L1b and CFL2 were included to normalize the
data. Eleven breast tumor samples, presenting either sin-
gle or multiple allelic imbalances within the probe
regions, were analyzed. MLPA analyses were conducted
as described above. Based on the MLPA results, allelic
imbalance of the fr.14 probe were confirmed in 64% (7/
11), for the fr.31 probe in 91% (10/11), and for the fr.32
probe in 73% (8/11) (figure 2). Cases with no CNV and
Figure 1 Establishment of MLPA reference probe quality by statistical analyses of results obtained from cohorts comprising unaffected 
and affected individuals, respectively. To ensure a normal distribution of the obtained data for the reference probes AFAP1Lb (A) and AFAP1La (B) 
in all analyzed cohorts, the z score and Q-Q plots were established based upon data from 48 unaffected individuals and 145 breast tumors (affected 
individuals). The z score based histograms and Q-Q plots for AFAP1Lb followed a normal distribution for both cohorts, and the reference probe was 
included in the study (A). Data obtained for the reference probe AFAP1La were not normally distributed as illustrated by the z score based histograms 
and the Q-Q plots for both cohorts. The probe was excluded from further studies (B).
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agreement between the two methods comprise 3 (fr. 14),
1 (fr. 31) and 4 (fr. 32) samples, are not included in figure
2. 
Our results strongly indicate that the MLPA probes
should be designed using exon sequences as templates.
The two intron-derived reference probes AFAP1L1a and
ACTR1A could not be successfully analyzed due to high
rate of variation between unaffected and affected individ-
uals. In contrast, the exon specific AFAP1L1b reference
probe presented normal distribution in both unaffected
a n d  a f f e c t e d  s a m p l e s  e n a b l i n g  t o  v a l i d a t e  M L P A  d a t a .
The same issue might concern the set of synthetic probes
designed to validate previously identified allelic imbal-
ances within the RGS8 in breast tumor samples. The tar-
get-specific probes in the RGS8 except the fr.31 probe
were designed in non-coding parts of the gene, due to
specific unsuitable sequence composition in the target
exons. The number of confirmed deletions was relatively
lower for these intron - based probes when compared to
fr.31. Different repeated sequences as SINE, LINE or Alu
repeats may interfere with the probe hybridization lower-
ing the specificity. Likewise, the presence of an yet
uncharacterized single nucleotide polymorphism (SNP)
may prevent hybridization or ligation of the probes [15].
Another possible reason for discrepancy in validating
CNV in breast cancer by MLP A might be due to non-
microdissected tumor DNA.
In conclusion, our approach using a group of unaf-
fected individuals to assess the quality of reference
probes, and obtain cut-off values for CNV is to our
knowledge new, and a solid supplement to existing analy-
sis software. The aim has been to present simple calcula-
tions to facilitate the use of the versatile MLPA
methodology especially in cancer research.
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(fr. 31) and 4 (fr. 32) samples, are not included in figure. The 95% CI from 
the normal distribution was used to set the cut-off value for amplifica-
tion above 1.96 and for the deletion below -1.96.
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